Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Consensus Price Target from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $16.00.

A number of equities analysts have weighed in on COYA shares. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday. BTIG Research raised their target price on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Lake Street Capital restated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Monday, November 24th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. CM Management LLC grew its position in shares of Coya Therapeutics by 50.0% during the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after acquiring an additional 100,000 shares during the period. Dauntless Investment Group LLC boosted its position in Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after purchasing an additional 101,932 shares in the last quarter. Citadel Advisors LLC grew its holdings in Coya Therapeutics by 51.3% in the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after purchasing an additional 22,120 shares during the period. Jane Street Group LLC increased its position in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after buying an additional 13,176 shares in the last quarter. Finally, Prosperity Wealth Management Inc. increased its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares in the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Stock Down 5.3%

Coya Therapeutics stock opened at $4.85 on Thursday. The firm’s fifty day moving average is $5.81 and its 200 day moving average is $6.04. The company has a market cap of $101.48 million, a price-to-earnings ratio of -4.37 and a beta of 0.25. Coya Therapeutics has a 52-week low of $4.65 and a 52-week high of $8.29.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.